Cited by 95Hematopoietic Stem Cell TransplantationTelomeres, Telomerase, and SenescenceTransplantation: Methods and Outcomes

Association Between Donor Leukocyte Telomere Length and Survival After Unrelated Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

Open access
Gadalla, Shahinaz M., Wang, Tao, Haagenson, Michael, Spellman, Stephen R., Lee, Stephanie J., Williams, Kirsten M., Wong, Jason Y., De Vivo, Immaculata +1 more·2015·JAMA

Abstract

IMPORTANCE: Telomeres protect chromosome ends and are markers of cellular aging and replicative capacity. OBJECTIVE: To evaluate the association between recipient and donor pretransplant leukocyte telomere length with outcomes after unrelated donor allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemia. DESIGN, PARTICIPANTS, AND SETTING: The study included 330 patients (235 acquired, 85 Fanconi anemia, and 10 Diamond-Blackfan anemia) and their unrelated donors who had pre-HCT blood samples and clinical and outcome data available at the Center for International Blood and Marrow Transplant Research. Patients underwent HCT between 1989 and 2007 in 84 centers and were followed-up to March 2013. EXPOSURES: Recipient and donor pre-HCT leukocyte telomere length classified into long (third tertile) and short (first and second tertiles combined) based on donor telomere length distribution. MAIN OUTCOMES AND MEASURES: Overall survival, neutrophil recovery, and acute and chronic graft-vs-host disease, as ascertained by transplant centers through regular patient follow-up. RESULTS: Longer donor leukocyte telomere length was associated with higher survival probability (5-year overall survival, 56%; number at risk, 57; cumulative deaths, 50) than shorter donor leukocyte telomere length (5-year overall survival, 40%; number at risk, 71; cumulative deaths, 128; P = .009). The association remained statistically significant after adjusting for donor age, disease subtype, Karnofsky performance score, graft type, HLA matching, prior aplastic anemia therapy, race/ethnicity, and calendar year of transplant (hazard ratio [HR], 0.61; 95% CI, 0.44-0.86). Similar results were noted in analyses stratified on severe aplastic anemia subtype, recipient age, HLA matching, calendar year of transplant, and conditioning regimen. There was no association between donor telomere length and neutrophil engraftment at 28 days (cumulative incidence, 86% vs 85%; HR, 0.94; 95% CI, 0.73-1.22), acute graft-vs-host disease grades III-IV at 100 days (cumulative incidence, 22% vs 28%; HR, 0.77; 95% CI, 0.48-1.23), or chronic graft-vs-host disease at 1-year (cumulative incidence, 28% vs 30%; HR, 0.81; 95% CI, 0.53-1.24) for long vs short, respectively. Pretransplant leukocyte telomere length in the recipients was not associated with posttransplant survival (HR, 0.91; 95% CI, 0.64-1.30). CONCLUSIONS AND RELEVANCE: Longer donor leukocyte telomere length was associated with increased 5-year survival in patients who received HCT for severe aplastic anemia. Patient leukocyte telomere length was not associated with survival. The results of this observational study suggest that donor leukocyte telomere length may have a role in long-term posttransplant survival.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2015.7

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Leukocyte telomere length in the donor, but not the recipient, positively correlates with survival after allogenic haematopoietic cell transplantation.

    “Leukocyte telomere length in the donor, but not in the recipient, positively correlates with survival following allogenic haematopoietic cell transplantation82.”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [82]

    The Conclusions and Results report that longer donor leukocyte telomere length was associated with better survival, while recipient telomere length was not. The study was limited to patients with severe aplastic anemia receiving unrelated-donor allogeneic HCT; the citing sentence leaves out that population and donor restriction. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gadalla, S. M., Wang, T., Haagenson, M., Spellman, S. R., Lee, S. J., Williams, K. M., Wong, J. Y., De Vivo, I., & Savage, S. A.
Affiliations
  • National Institutes of Health (US)
  • Medical College of Wisconsin (US)
  • Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota
  • Children's National (US)
  • Brigham and Women's Hospital (US)
  • Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts8Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts
Venue
JAMA
Published
2015-02-10
Volume
313
Issue
6
Pages
594
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2081316165
Cited by
95
References
37
Citations by year
2026: 5 · 2025: 8 · 2024: 11 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 10 · 2017: 12 · 2016: 12 · 2015: 3
FWCI
9.68
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (Z99 CA999999)
  • U.S. Public Health Service (HHSH234200637015C)
  • National Heart, Lung, and Blood Institute (HHSH234200637015C, N00014-13-1-0039, U24‐CA76518)
  • Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028, N00014)
  • National Cancer Institute (U24CA76518, R01CA082838, U24CA076518, HHSH234200637015C)
  • National Institute of Allergy and Infectious Diseases (U24-CA76518, HHSH234200637015C)
Topics
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
severe aplastic anemia, Fanconi anemia, Diamond-Blackfan anemia, overall survival, graft-versus-host disease, neutrophil engraftment, donor age, HLA matching, conditioning regimen, cellular aging
MeSH terms
Adolescent, Adult, Anemia, Aplastic, Child, Child, Preschool, Female, Humans, Infant, Leukocytes, Male, Middle Aged, Tissue Donors, Transplantation, Homologous, Telomere, Hematopoietic Stem Cell Transplantation, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review